Health Trials

Clinical trials

7

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jul 13, 2026Locations: 15
Eligibility criteria

Histopathology confirmed PDAC [+3]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Not yet recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Participants needed: 105
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jul 13, 2026Locations: 3
Eligibility criteria

Histopathology confirmed unresectable locally advanced or metastatic NSCLC [+10]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jul 2, 2026Locations: 14
Eligibility criteria

Histopathology confirmed PDAC [+3]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Not yet recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Participants needed: 150
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jun 22, 2026
Eligibility criteria

Histopathology confirmed metastatic CRC [+7]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Not yet recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Participants needed: 105
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jun 22, 2026
Eligibility criteria

Histopathology confirmed unresectable locally advanced or metastatic NSCLC [+10]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Participants needed: 295
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Apr 22, 2026Locations: 14
Eligibility criteria

Individuals ≥18 years of age. [+8]

Underwent major surgical procedure as defined by the Investigator, other than fo... [+7]

Read more
Status: Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Participants needed: 270
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Verastem, Inc.Updated: Apr 2, 2026Locations: 106
Eligibility criteria

Histologically proven LGSOC (ovarian, fallopian, peritoneal) [+9]

Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy. [+16]

Read more